AEON Biopharma, Inc. Overview
Pro stress-test →AEON Biopharma is a clinical stage biopharmaceutical company focused on developing botulinum toxins. The company is the only one dedicated exclusively to the use of botulinum toxins for therapeutic-only indications. It is advancing ABP-450 as a proposed biosimilar to BOTOX for therapeutic indications using the FDA's 351(k) biosimilar pathway.
Strategic Profile
Pro stress-test →ABP-450 has completed Phase 2 studies for cervical dystonia and has ongoing Phase 2 studies for chronic and episodic migraine, plus development for gastroparesis and post-traumatic stress disorder. The company held a BPD Type 2a meeting with the FDA on January 21, 2026 to review its analytical development plan and initial biosimilarity data. The company has license agreements with Daewoong Pharmaceutical and Viatris Inc.
Competitive Landscape
Pro stress-test →AEON operates in the therapeutic botulinum toxin market, competing against established players like Allergan/AbbVie (BOTOX) and Revance (Daxxify). The biosimilar pathway strategy targets the large migraine and dystonia markets, but faces competition from other botulinum toxin manufacturers and potential generic/biosimilar entrants.
Industry Context
AEON Biopharma, Inc. operates in Biotechnology / Biopharmaceuticals.
Key facts
Founded: 2012 · Headquarters: Irvine, California · Employees: 9 · Market cap: $26.3M